Professor Zoe Winters - Breast Cancer Consultant & Breast Specialist

07/11/2025

Low-Risk DCIS may be safely managed by no surgery or active monitoring

Low risk ductal cancer in situ (DCIS) comprises pre-invasive breast cancer cells that are very slow growing and behave like other benign lesions with atypical cells. The risk of low-risk DCIS becoming an invasive cancer at 10 years is under 11%.

A large study in the USA on 1780 women with low-risk DCIS showed that 6 monthly mammograms compared to surgery was likely to be clinically safe with no differences in cancer outcomes at 8 years.

Ryser MD, Cancer outcomes in women without upfront surgery for ductal
carcinoma in situ: observational cohort study. BMJ 2025

🔗https://www.bmj.com/content/390/bmj-2024-083542

31/10/2025

10/10/2025

For Breast Cancer Awareness Month (October 2025), Helen, one of our many courageous patients has shared her personal story, in the hope that this gives inspiration to others who face this difficult journey. 🎀🎗

I think you'll all agree, Helen's spirit and determination greatly shines through.....

You look amazing, Helen Faulkner 😍



The Lister Hospital
Breast Cancer Now

"That's your treatment done", best words I ever heard. I did a little dance to myself in the changing room!

08/10/2025

It only takes a few minutes.
Early detection will save lives.
Please check your breasts regularly.

25/09/2025

World Dense Breast Day - 24th September

In case you missed it, and you wish to learn more about this incredibly important subject - use the link below. All information provided by, DenseBreast-info, Inc

🔗 under latest news - world dense breast day

https://londonbreasthealth.com/news-updates/

https://londonbreasthealth.com/wp-content/uploads/2025/09/World-Dense-Breast-Day-September-24th.pdf

08/09/2025

This PARTNER trial is new and exciting as the benefits of using Olaparib before surgery (neoadjuvant) were unproven until now.

Women with early breast cancers that are triple negative, and / or carry a BRCA gene mutation showed 100% survival at 3 years after being treated with upfront or neoadjuvant combined chemotherapy and the drug called Olaparib, which is called a PARP inhibitor (PARPi).

Olaparib causes more damage to the cancer cells when combined with chemotherapy. This means when using this combined treatment before surgery, there is a greater potential for a complete pathological response of the cancer, or complete killing of the invasive cancer cells. This type of complete cancer cell killing improves individual overall survival.

https://londonbreasthealth.com/wp-content/uploads/2025/09/PARTNER-trial-Nat-Comms-2025-.pdf

12/08/2025

Advances in early breast cancer detection mean that most older women do not require armpit surgery. This therefore eliminates lymphoedema, pain, loss of arm sensation and swelling, which are all side effects from armpit (axillary) surgery.

1. No routine recommendation for sentinel lymph node biopsy (SLNB) in early breast cancer.
Postmenopausal women >= 50 years
Cancer

24/07/2025

Outstanding clinical trial results in metastatic and advanced oestrogen positive (ER+) HER2 negative breast cancers that shows prolonged progression free survival.

ASCO 2025 New drug target for metastatic / advanced Hormone Receptor Positive Breast Cancer

INAVO Phase III International randomised double -blind placebo-controlled trial

Metastatic and advanced hormone receptor positive (HR+) HER2 negative breast cancers acquire treatment resistance to endocrine treatments such as: Cyclin Dependent Kinase Inhibitor or CDKI (Palbociclib) and Faslodex (selective oestrogen receptor degrader or SERD).

Circulating cancer DNA or tissue DNA is used to measure a key treatment target called a PIK3CA mutation that occurs in 40% of patients.

Inavolisib targets PIK3CA to produce significant increases in cancer Progression Free Survival from 7 months (placebo) to 17 months (Inavolisib) over 34 months, when combined with Palbociclib and Faslodex.

Objective cancer response rates are significantly higher from 28% (placebo) to
63% (Inavolisib), with a duration of response from 11 months (placebo) to 19 months (Inavolisib).

See link: https://pubmed.ncbi.nlm.nih.gov/39476340/

In patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer, inavolisib plus palbociclib-fulvestrant led to significantly longer progression-free survival than placebo plus palbociclib-fulvestrant, with a greater incidence of toxic ef...

17/07/2025

HRT and Breast Cancer Risks explained.

Body and bio-identical combined HRT use over 5 years is likely to increase breast cancer risks slightly (1 extra cancer in 100 women).

We are awaiting data on the specific risks in large numbers of women that will provide greater reassurance for women who wish to use HRT for 10 years or more.

Specialist breast care and regular screening is important in all women, and should be discussed with your specialist.

Modern HRT should comprise body & bio identical types with optimal administration in the context of individual breast cancer risks.

17/07/2025

Honoured to be awarded the badge 'great patient experience' from Doctify.

😀 🎗

01/07/2025

The power of translational medicine "from bench to bedside" at ASCO 2025 is shown by measuring circulating tumour DNA in blood that detects breast cancer mutations in women with advanced metastatic oestrogen receptor positive (ER+) and HER2 negative (0) breast cancer.

Women taking aromatase inhibitors and a CDK4/6 inhibitor can develop an early mutation of the oestrogen receptor called ESR1, which is detected in blood about 21 months after starting treatment. This occured before any clinical evidence of cancer progression on imaging.

The SERENA-6 trial shows significant progression-free survival benefits in women who then received a next generation drug called Camizestrant that degrades and totally blocks the oestrogen receptor called a SERD (Selective Oestrogen Receptor Degrader). Camizestrant treats ESR1 mutated cancers more effectively than an aromatase inhibitor or faslodex combined with CDK4/6 inhibitors.

https://pubmed.ncbi.nlm.nih.gov/40454637/

17/06/2025

Important facts for young women (less than and equal to 50 years of age), who have been diagnosed with breast cancer. Part 1.